CEPHADEX 250

32% OFF
32% OFF

Original price was: ₹95.16.Current price is: ₹65.00.

Product Name: CEPHADEX 250 DT Tablet
Company: Cipla Ltd.
Salt Composition: Cefalexin (250 mg)

10.0 capsules in 1 strip

Buy Now
Category:

Description

CEPHADEX 250 DT Tablet is an antibiotic medicine from Cipla Ltd., containing Cefalexin 250 mg, a first-generation cephalosporin antibiotic. It is widely prescribed for the treatment of bacterial infections in both adults and children.

Cefalexin works by inhibiting bacterial cell wall synthesis, which weakens and kills bacteria, thereby stopping the infection from spreading and promoting faster recovery.


Uses:

  • Respiratory tract infections: Tonsillitis, pharyngitis, bronchitis, pneumonia

  • Ear, nose, and throat infections

  • Urinary tract infections (UTIs)

  • Skin and soft tissue infections

  • Bone and joint infections


Key Benefits:

  • Effective against gram-positive bacteria and some gram-negative bacteria

  • Dispersible tablet (DT) form makes it easy to administer, especially for children

  • Provides relief from fever, pain, swelling, redness, and discomfort caused by infections

  • Helps prevent the spread of bacterial infections


How to Take:

  • Take as prescribed by the doctor

  • Can be swallowed directly or dissolved in water before administration

  • Complete the full prescribed course, even if symptoms improve early


Precautions:

  • Not effective against viral infections such as cold or flu

  • Inform your doctor if you have a history of allergy to penicillins or cephalosporins

  • Dose adjustment may be needed in kidney disease

  • Use in pregnancy or breastfeeding only under medical supervision


Possible Side Effects:

  • Mild: Diarrhea, nausea, vomiting, stomach pain, mild rash

  • Rare but serious: Severe allergic reactions, persistent diarrhea (C. difficile infection)


Storage:

  • Store in a cool, dry place below 25°C

  • Keep out of reach of children and away from direct sunlight

Leave a Reply

Your email address will not be published. Required fields are marked *